Investor Relations

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

Recent Releases

Date Title and Summary
Toggle Summary Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs
-CDX-0159 IND accepted; Phase 1 study to start by YE 2019- -CDX-527 on track for IND filing in 1H 2020- HAMPTON, N.J. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX)  presented data from the Company’s preclinical pipeline this weekend.
Toggle Summary CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study- -Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity- -Clinical trial collaboration with Merck announced to evaluate CDX-1140 with KEYTRUDA®- HAMPTON, N.J. , Nov.

Upcoming Events

There are currently no events to display.

Featured Financial Reports

Show all

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline